KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash & Equivalents (2018 - 2025)

Castle Biosciences' Cash & Equivalents history spans 7 years, with the latest figure at $116.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 2.49% year-over-year to $116.7 million; the TTM value through Dec 2025 reached $116.7 million, down 2.49%, while the annual FY2025 figure was $116.7 million, 2.49% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $116.7 million at Castle Biosciences, up from $85.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $407.0 million in Q1 2021 and bottomed at $82.2 million in Q2 2025.
  • The 5-year median for Cash & Equivalents is $115.8 million (2023), against an average of $173.3 million.
  • The largest annual shift saw Cash & Equivalents soared 312.54% in 2021 before it tumbled 64.89% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $329.6 million in 2021, then crashed by 62.7% to $122.9 million in 2022, then dropped by 19.61% to $98.8 million in 2023, then increased by 21.11% to $119.7 million in 2024, then decreased by 2.49% to $116.7 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Cash & Equivalents are $116.7 million (Q4 2025), $85.6 million (Q3 2025), and $82.2 million (Q2 2025).